Candel Therapeutics (CADL) Liabilities and Shareholders Equity (2020 - 2025)

Candel Therapeutics has disclosed Liabilities and Shareholders Equity across 6 years of filings, most recently posting $125.2 million for Q4 2025.

• Liabilities and Shareholders Equity for Q4 2025 came in at $125.2 million, up 17.15% year-over-year; the trailing twelve-month figure through Dec 2025 was $420.7 million (up 126.06% YoY), and the FY2025 annual result was $125.2 million, up 17.15% from the prior year.
• Liabilities and Shareholders Equity came in at $125.2 million for Q4 2025 at Candel Therapeutics, up from $93.6 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $125.2 million in Q4 2025 to a low of $21.5 million in Q3 2024.
• The 5-year median for Liabilities and Shareholders Equity is $85.0 million (2022), against an average of $73.5 million.
• Across the five-year window, Liabilities and Shareholders Equity plunged 57.02% in 2024 and surged 335.0% in 2025, its largest moves.
• Candel Therapeutics' Liabilities and Shareholders Equity stood at $89.2 million in 2021, then decreased by 12.91% to $77.7 million in 2022, then plunged by 46.97% to $41.2 million in 2023, then soared by 159.38% to $106.9 million in 2024, then gained by 17.15% to $125.2 million in 2025.
• The last three Liabilities and Shareholders Equity figures came in at $125.2 million (Q4 2025), $93.6 million (Q3 2025), and $106.0 million (Q2 2025), per Business Quant data.